QIAGEN Operating Margin 2010-2023 | QGEN
Current and historical operating margin for QIAGEN (QGEN) over the last 10 years. The current operating profit margin for QIAGEN as of March 31, 2023 is 24.02%.
| QIAGEN Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2023-03-31 |
$2.00B |
$0.42B |
21.11% |
| 2022-12-31 |
$2.14B |
$0.53B |
24.84% |
| 2022-09-30 |
$2.23B |
$0.60B |
26.95% |
| 2022-06-30 |
$2.26B |
$0.63B |
28.04% |
| 2022-03-31 |
$2.31B |
$0.67B |
29.11% |
| 2021-12-31 |
$2.25B |
$0.63B |
27.99% |
| 2021-09-30 |
$2.24B |
$0.61B |
27.37% |
| 2021-06-30 |
$2.19B |
$0.53B |
24.03% |
| 2021-03-31 |
$2.07B |
$0.48B |
23.44% |
| 2020-12-31 |
$1.87B |
$0.39B |
20.70% |
| 2020-09-30 |
$1.71B |
$0.31B |
18.17% |
| 2020-06-30 |
$1.61B |
$0.06B |
3.66% |
| 2020-03-31 |
$1.55B |
$0.00B |
0.00% |
| 2019-12-31 |
$1.53B |
$-0.03B |
-1.70% |
| 2019-09-30 |
$1.52B |
$-0.02B |
-1.19% |
| 2019-06-30 |
$1.51B |
$0.27B |
17.59% |
| 2019-03-31 |
$1.51B |
$0.26B |
17.19% |
| 2018-12-31 |
$1.50B |
$0.27B |
17.71% |
| 2018-09-30 |
$1.50B |
$0.22B |
14.77% |
| 2018-06-30 |
$1.48B |
$0.21B |
14.04% |
| 2018-03-31 |
$1.45B |
$0.18B |
12.17% |
| 2017-12-31 |
$1.42B |
$0.15B |
10.79% |
| 2017-09-30 |
$1.39B |
$0.11B |
8.21% |
| 2017-06-30 |
$1.36B |
$0.10B |
7.19% |
| 2017-03-31 |
$1.35B |
$0.11B |
7.86% |
| 2016-12-31 |
$1.34B |
$0.10B |
7.40% |
| 2016-09-30 |
$1.32B |
$0.15B |
11.59% |
| 2016-06-30 |
$1.30B |
$0.15B |
11.65% |
| 2016-03-31 |
$1.28B |
$0.16B |
12.57% |
| 2015-12-31 |
$1.28B |
$0.18B |
13.97% |
| 2015-09-30 |
$1.29B |
$0.14B |
10.99% |
| 2015-06-30 |
$1.31B |
$0.15B |
11.12% |
| 2015-03-31 |
$1.33B |
$0.15B |
11.62% |
| 2014-12-31 |
$1.34B |
$0.16B |
11.98% |
| 2014-09-30 |
$1.35B |
$0.17B |
12.94% |
| 2014-06-30 |
$1.33B |
$0.16B |
11.87% |
| 2014-03-31 |
$1.32B |
$0.08B |
5.78% |
| 2013-12-31 |
$1.30B |
$0.06B |
4.84% |
| 2013-09-30 |
$1.29B |
$0.08B |
6.06% |
| 2013-06-30 |
$1.27B |
$0.08B |
6.54% |
| 2013-03-31 |
$1.26B |
$0.16B |
12.84% |
| 2012-12-31 |
$1.25B |
$0.17B |
13.48% |
| 2012-09-30 |
$1.24B |
$0.10B |
8.06% |
| 2012-06-30 |
$1.23B |
$0.10B |
7.75% |
| 2012-03-31 |
$1.20B |
$0.10B |
7.99% |
| 2011-12-31 |
$1.17B |
$0.10B |
8.38% |
| 2011-09-30 |
$1.12B |
$0.17B |
15.08% |
| 2011-06-30 |
$1.11B |
$0.19B |
16.73% |
| 2011-03-31 |
$1.09B |
$0.18B |
16.74% |
| 2010-12-31 |
$1.09B |
$0.19B |
17.39% |
| 2010-09-30 |
$1.09B |
$0.17B |
15.87% |
| 2010-06-30 |
$1.08B |
$0.18B |
16.36% |
| 2010-03-31 |
$1.05B |
$0.18B |
17.47% |
| 2009-12-31 |
$1.01B |
$0.18B |
17.82% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.584B |
$2.142B |
|
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
|
